-
公开(公告)号:US11155542B2
公开(公告)日:2021-10-26
申请号:US16335384
申请日:2017-09-21
申请人: Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie E.V. Hans-Knöll Institut (HKI) , Klinikum der Universität München , University of Notre Dame du Lac, Office of Technology Transfer
发明人: Florian Kloss , Sebastian Schieferdecker , Axel Brakhage , Julia Dreisbach , Marvin J. Miller , Ute Mollmann , Kamil Philip Wojtas
IPC分类号: C07D513/04 , A61P31/04 , A61P31/06 , C07D417/04
摘要: The present invention relates to the general field of treatment of infectious diseases of mammals (humans and animals) caused by bacteria, in particular to the treatment of diseases like tuberculosis (TB), Buruli ulcer and leprosy caused by mycobacteria. The invention aims at the generation of a new series of benzothiazinone compounds having the potential to overcome the above mentioned problems. In a preferred embodiment the invention is concerned with compounds of the general formula (I) wherein R1 represents NO2, R2 represents CF3, at least one of the substituents R3 and R4 is OH, SR14, NHR15, CN, N3, a saturated or unsaturated, optionally halogenated, linear or branched aliphatic radical having 1-4 carbon atoms, linear or branched C1-C4 alkoxy, C1-C4 acyl, and the other of R3 and R4 may in addition be hydrogen, R6 represents a 2-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl or a 4-(cyclo-hexylmethyl)piperazin-1-yl group and R14 and R15 independently of each other are hydrogen or a C1-C4 alkyl group and/or a pharmaceutically acceptable salt thereof.